Tetraphase Pharmaceuticals (TTPH) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Tetraphase Pharmaceuticals (TTPH) Posts Quarterly  Earnings Results, Beats Expectations By $0.03 EPS

Tetraphase Pharmaceuticals (NASDAQ:TTPH) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.03, Morningstar.com reports. Tetraphase Pharmaceuticals had a negative net margin of 381.71% and a negative return on equity of 72.26%. The business had revenue of $1.27 million during the quarter, compared to analysts’ expectations of $1.93 million.

TTPH traded down $0.07 during midday trading on Thursday, reaching $1.00. 1,300 shares of the company’s stock were exchanged, compared to its average volume of 615,794. The stock has a market cap of $58.06 million, a price-to-earnings ratio of -0.73 and a beta of 2.85. The company has a quick ratio of 7.73, a current ratio of 7.78 and a debt-to-equity ratio of 0.36. Tetraphase Pharmaceuticals has a one year low of $0.95 and a one year high of $4.49.

Several equities research analysts recently weighed in on TTPH shares. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 26th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday. Piper Jaffray Companies reduced their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a research note on Friday, March 15th. Finally, Gabelli cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 target price for the company. in a research note on Friday, March 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $4.09.

Institutional investors and hedge funds have recently made changes to their positions in the business. Paloma Partners Management Co bought a new position in shares of Tetraphase Pharmaceuticals in the fourth quarter valued at approximately $33,000. Gamco Investors INC. ET AL raised its stake in shares of Tetraphase Pharmaceuticals by 42.9% in the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 15,000 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Tetraphase Pharmaceuticals in the fourth quarter valued at approximately $69,000. Rhumbline Advisers raised its stake in shares of Tetraphase Pharmaceuticals by 40.6% in the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 21,089 shares during the last quarter. Finally, Alambic Investment Management L.P. raised its stake in shares of Tetraphase Pharmaceuticals by 31.0% in the fourth quarter. Alambic Investment Management L.P. now owns 114,874 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 27,170 shares during the last quarter. Hedge funds and other institutional investors own 43.39% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: Strike Price

Related posts

Leave a Comment